[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fPlVWbV8yrqRmySlG4qaXbg88700cI0TvAbii-NMSho4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"Butler Hospital",[4],116,false,21,16,56698,3,100,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Depression",18,{"name":18,"count":19},"Suicide",8,{"name":21,"count":22},"Major Depressive Disorder",6,{"name":24,"count":22},"HIV",{"name":26,"count":22},"Obsessive-Compulsive Disorder",{"name":28,"count":29},"Suicide and Self-harm",5,{"name":31,"count":29},"Suicidal Ideation",{"name":33,"count":34},"Bipolar Disorder",4,[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05206435","Methadone-Maintained Smokers Switching to E-Cigarettes","2025-06-30","Electronic Cigarette",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04500847","Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD","2026-03-31","Emtriva",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,80,98,122,148,174,198,224,250,268,294,319,344,369,395,451,474,492],{"intervention":40,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":66,"NA":78},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":59},[],{"trials":67,"activeCount":55,"soonestReadout":39},[68],{"nctId":37,"briefTitle":38,"status":69,"phases":70,"primaryCompletion":39,"completion":39,"start":71,"enrollment":72,"conditions":73,"interventions":76},"ACTIVE_NOT_RECRUITING",[51],"2022-03-31",240,[74,75],"Nicotine Dependence","Electronic Cigarette Use",[40,77],"Nicotine Lozenge",{"trials":79,"activeCount":59},[],{"intervention":77,"totalTrials":55,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":90,"NA":96},{"trials":83,"activeCount":59},[],{"trials":85,"activeCount":59},[],{"trials":87,"activeCount":59},[],{"trials":89,"activeCount":59},[],{"trials":91,"activeCount":55,"soonestReadout":39},[92],{"nctId":37,"briefTitle":38,"status":69,"phases":93,"primaryCompletion":39,"completion":39,"start":71,"enrollment":72,"conditions":94,"interventions":95},[51],[74,75],[40,77],{"trials":97,"activeCount":59},[],{"intervention":45,"totalTrials":55,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":120},{"trials":101,"activeCount":59},[],{"trials":103,"activeCount":55,"soonestReadout":44},[104],{"nctId":42,"briefTitle":43,"status":105,"phases":106,"primaryCompletion":44,"completion":44,"start":107,"enrollment":108,"conditions":109,"interventions":113},"RECRUITING",[48],"2021-12-17",35,[110,111,112],"Alzheimer Disease, Early Onset","Mild Cognitive Impairment","Moderate Dementia",[45],{"trials":115,"activeCount":59},[],{"trials":117,"activeCount":59},[],{"trials":119,"activeCount":59},[],{"trials":121,"activeCount":59},[],{"intervention":123,"totalTrials":55,"cells":124},"Levetiracetam",{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":146},{"trials":126,"activeCount":59},[],{"trials":128,"activeCount":59},[],{"trials":130,"activeCount":59},[],{"trials":132,"activeCount":59},[],{"trials":134,"activeCount":59},[135],{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT00265109","Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder","COMPLETED",[51],"2008-01","2004-12",17,[144],"Body Dysmorphic Disorder",[123],{"trials":147,"activeCount":59},[],{"intervention":149,"totalTrials":55,"cells":150},"eszopiclone",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":172},{"trials":152,"activeCount":59},[],{"trials":154,"activeCount":59},[],{"trials":156,"activeCount":59},[],{"trials":158,"activeCount":59},[],{"trials":160,"activeCount":59},[161],{"nctId":162,"briefTitle":163,"status":138,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"NCT00889200","Eszopiclone Treatment & Cortisol Responsivity",[51],"2008-12","2009-08","2007-05",12,[170],"Insomnia",[149],{"trials":173,"activeCount":59},[],{"intervention":175,"totalTrials":55,"cells":176},"Suboxone",{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":194,"NA":196},{"trials":178,"activeCount":59},[],{"trials":180,"activeCount":59},[],{"trials":182,"activeCount":59},[],{"trials":184,"activeCount":59},[185],{"nctId":186,"briefTitle":187,"status":138,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":8,"conditions":191,"interventions":193},"NCT02696096","Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence",[50],"2020-02","2016-08",[192],"Opioid Addiction",[175],{"trials":195,"activeCount":59},[],{"trials":197,"activeCount":59},[],{"intervention":199,"totalTrials":55,"cells":200},"Antidepressant Medication",{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":220,"NA":222},{"trials":202,"activeCount":59},[],{"trials":204,"activeCount":59},[],{"trials":206,"activeCount":59},[],{"trials":208,"activeCount":59},[209],{"nctId":210,"briefTitle":211,"status":138,"phases":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":219},"NCT00228007","Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users",[50],"2004-09","2000-09",265,[15,217,218],"Substance-Related Disorders","HIV Infections",[199],{"trials":221,"activeCount":59},[],{"trials":223,"activeCount":59},[],{"intervention":225,"totalTrials":55,"cells":226},"Fluoxetine",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":246,"NA":248},{"trials":228,"activeCount":59},[],{"trials":230,"activeCount":59},[],{"trials":232,"activeCount":59},[],{"trials":234,"activeCount":59},[235],{"nctId":236,"briefTitle":237,"status":138,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},"NCT00578669","Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms",[50],"2013-07","2013-11","2008-04",206,[21,74,15],[225,245],"Dextrose",{"trials":247,"activeCount":59},[],{"trials":249,"activeCount":59},[],{"intervention":245,"totalTrials":55,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":264,"NA":266},{"trials":253,"activeCount":59},[],{"trials":255,"activeCount":59},[],{"trials":257,"activeCount":59},[],{"trials":259,"activeCount":59},[260],{"nctId":236,"briefTitle":237,"status":138,"phases":261,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":262,"interventions":263},[50],[21,74,15],[225,245],{"trials":265,"activeCount":59},[],{"trials":267,"activeCount":59},[],{"intervention":269,"totalTrials":55,"cells":270},"Trazodone",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":290,"NA":292},{"trials":272,"activeCount":59},[],{"trials":274,"activeCount":59},[],{"trials":276,"activeCount":59},[],{"trials":278,"activeCount":59},[279],{"nctId":280,"briefTitle":281,"status":138,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":289},"NCT00253890","Insomnia and Drug Relapse Risk",[50],"2010-05","2005-10",137,[287,288],"Poor Quality Sleep","Opiate Addiction",[269],{"trials":291,"activeCount":59},[],{"trials":293,"activeCount":59},[],{"intervention":295,"totalTrials":55,"cells":296},"escitalopram",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":315,"NA":317},{"trials":298,"activeCount":59},[],{"trials":300,"activeCount":59},[],{"trials":302,"activeCount":59},[],{"trials":304,"activeCount":59},[305],{"nctId":306,"briefTitle":307,"status":138,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT00475878","SSRI and Buprenorphine",[50],"2009-09","2006-12",147,[313,15],"Opiate Dependence",[295],{"trials":316,"activeCount":59},[],{"trials":318,"activeCount":59},[],{"intervention":320,"totalTrials":55,"cells":321},"Risperidone",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":323,"activeCount":59},[],{"trials":325,"activeCount":59},[],{"trials":327,"activeCount":59},[328],{"nctId":329,"briefTitle":330,"status":331,"phases":332,"primaryCompletion":333,"completion":333,"start":334,"enrollment":59,"conditions":335,"interventions":337},"NCT00000309","Serotonin\u002FDopamine Antagonism of Cocaine Effect: 1 - 1","TERMINATED",[49],"2000-01","1994-08",[336],"Cocaine-Related Disorders",[320],{"trials":339,"activeCount":59},[],{"trials":341,"activeCount":59},[],{"trials":343,"activeCount":59},[],{"intervention":345,"totalTrials":55,"cells":346},"Medication prescribed by PCP",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":348,"activeCount":59},[],{"trials":350,"activeCount":59},[351],{"nctId":352,"briefTitle":353,"status":138,"phases":354,"primaryCompletion":309,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT00541957","Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients",[48],"2010-01","2007-04",40,[359],"Major Depression",[345],{"trials":362,"activeCount":59},[],{"trials":364,"activeCount":59},[],{"trials":366,"activeCount":59},[],{"trials":368,"activeCount":59},[],{"intervention":370,"totalTrials":55,"cells":371},"L-theanine",{"EARLY_PHASE1":372,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":393},{"trials":373,"activeCount":59},[374],{"nctId":375,"briefTitle":376,"status":138,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":384},"NCT04749745","Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study",[47],"2021-05-31","2020-06-09",11,[382,383],"Cortical Excitability","Psychiatric Disorder",[370],{"trials":386,"activeCount":59},[],{"trials":388,"activeCount":59},[],{"trials":390,"activeCount":59},[],{"trials":392,"activeCount":59},[],{"trials":394,"activeCount":59},[],{"intervention":396,"totalTrials":11,"cells":397},"varenicline",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":408},{"trials":399,"activeCount":59},[],{"trials":401,"activeCount":59},[],{"trials":403,"activeCount":59},[],{"trials":405,"activeCount":59},[],{"trials":407,"activeCount":59},[],{"trials":409,"activeCount":59},[410,421,442],{"nctId":411,"briefTitle":412,"status":413,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":59,"conditions":417,"interventions":420},"NCT00525928","Mood and Anti-craving Effects of Varenicline in Psychiatric Inpatients","WITHDRAWN",[52],"2008-10","2007-10",[418,419],"Smoking","Depressive Disorder",[396],{"nctId":422,"briefTitle":423,"status":138,"phases":424,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":440},"NCT00790569","Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking",[52],"2012-10","2008-09",315,[429,430,431,432,433,434,435,436,437,438,439],"Bladder Cancer","Cervical Cancer","Esophageal Cancer","Gastric Cancer","Head and Neck Cancer","Kidney Cancer","Leukemia","Liver Cancer","Lung Cancer","Pancreatic Cancer","Tobacco Use Disorder",[441,396],"nicotine",{"nctId":443,"briefTitle":444,"status":138,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":16,"conditions":448,"interventions":449},"NCT00525837","Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers",[52],"2008-03","2007-09",[419,418],[450,396],"fixed dose varenicline",{"intervention":452,"totalTrials":55,"cells":453},"Transdermal Nicotine",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":455,"activeCount":59},[],{"trials":457,"activeCount":59},[],{"trials":459,"activeCount":59},[],{"trials":461,"activeCount":59},[],{"trials":463,"activeCount":59},[],{"trials":465,"activeCount":59},[466],{"nctId":467,"briefTitle":468,"status":138,"phases":469,"primaryCompletion":470,"completion":471,"start":309,"enrollment":6,"conditions":472,"interventions":473},"NCT01061528","Coping Skills Treatment for Smoking Cessation",[52],"2013-08","2013-10",[74],[452],{"intervention":441,"totalTrials":55,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":477,"activeCount":59},[],{"trials":479,"activeCount":59},[],{"trials":481,"activeCount":59},[],{"trials":483,"activeCount":59},[],{"trials":485,"activeCount":59},[],{"trials":487,"activeCount":59},[488],{"nctId":422,"briefTitle":423,"status":138,"phases":489,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":490,"interventions":491},[52],[429,430,431,432,433,434,435,436,437,438,439],[441,396],{"intervention":450,"totalTrials":55,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":502,"NA":504},{"trials":495,"activeCount":59},[],{"trials":497,"activeCount":59},[],{"trials":499,"activeCount":59},[],{"trials":501,"activeCount":59},[],{"trials":503,"activeCount":59},[],{"trials":505,"activeCount":59},[506],{"nctId":443,"briefTitle":444,"status":138,"phases":507,"primaryCompletion":446,"completion":446,"start":447,"enrollment":16,"conditions":508,"interventions":509},[52],[419,418],[450,396]]